{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:13:24Z","timestamp":1792145604377,"version":"4.4.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Epidermolysis bullosa acquisita (EBA) is a chronic, recurrent autoimmune subepidermal bullous disease characterized by the presence of autoantibodies targeting type VII collagen -- basement membrane zone antigen. Standard therapy for EBA includes a combination of systemic corticosteroids and dapsone; however, severe cases may require advanced treatment. The current article reports on four EBA cases in which biologics: infliximab, rituximab (Rtx), and intravenous immunoglobulin (IVIG) were applied. All patients fulfilled the clinical and immunological criteria of EBA: they presented tense blisters healing with atrophic scars on the skin on traumatized areas and in mucous membranes. The diagnosis of EBA was established using numerous techniques: direct and indirect immunofluorescence, salt split skin, ELISA, Fluorescence Overlay Antigen Mapping using Laser Scanning Confocal Microscopy. Since all the patients did not achieve long-term remission on standard treatment (prednisone, dapsone) due to ineffectiveness or side effects of drugs, they eventually were treated with biologics leading to extraordinary skin improvement and stopping the disease for 1-3 years. Biologics in all patients were tolerated very well. No side effects were observed during application as well as multi-month follow-up. The presented cases provide a premise that biological drugs can be a valuable component of EBA therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1214011","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T18:35:11Z","timestamp":1689186911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Konrad","family":"Szyma\u0144ski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Kowalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Pietrzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198404193101602","article-title":"Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita","volume":"310","author":"Woodley","year":"1984","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","article-title":"Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients","volume":"13","author":"Iwata","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70107-D","article-title":"Childhood epidermolysis bullosa acquisita. report of three cases and review of literature","volume":"24","author":"Arpey","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14722","article-title":"Pediatric epidermolysis bullosa acquisita: a review","volume":"38","author":"Hignett","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2009.01.012","article-title":"[Epidermolysis bullosa acquisita of childhood]","volume":"136","author":"Bordier-Lamy","year":"2009","journal-title":"Ann Dermatol Venereol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/JID.2015.356","article-title":"Epidermolysis bullosa acquisita: from pathophysiology to novel therapeutic options","volume":"136","author":"Kasperkiewicz","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00513-3","article-title":"A review comparing international guidelines for the management of bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, and epidermolysis bullosa acquisita","volume":"21","author":"Patel","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1103533","article-title":"Risk factors and sequelae of epidermolysis bullosa acquisita: a propensity-matched global study in 1,344 patients","volume":"13","author":"Kridin","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"bcr2015210210","DOI":"10.1136\/bcr-2015-210210","article-title":"Epidermolysis bullosa acquisita in a 17-year-old boy with crohn\u2019s disease","volume":"2015","author":"Russo","year":"2015","journal-title":"BMJ Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2009.00959.x","article-title":"Autoimmunity against type VII collagen in inflammatory bowel disease","volume":"14","author":"Hundorfean","year":"2010","journal-title":"J Cell Mol Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.01772.x","article-title":"The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn\u2019s disease have autoantibodies to type VII collagen","volume":"118","author":"Chen","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2015.00206","article-title":"Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment","volume":"22","author":"Hirose","year":"2016","journal-title":"Mol Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2050313X2210916","DOI":"10.1177\/2050313X221091600","article-title":"Epidermolysis bullosa acquisita treated with ustekinumab: a case report","volume":"10","author":"Prosty","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12114","article-title":"Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literature","volume":"38","author":"Reddy","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03340130064034","article-title":"Epidermolysis bullosa acquisita and inflammatory bowel disease","volume":"250","author":"Raab","year":"1983","journal-title":"JAMA"},{"key":"B16","first-page":"234","article-title":"Epidermolysis bullosa acquisita and crohn\u2019s disease","volume":"66","author":"Pegum","year":"1973","journal-title":"Proc R Soc Med"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.2340\/0001555558241244","article-title":"Epidermolysis bullosa acquisita and crohn\u2019s disease","volume":"58","author":"Livden","year":"1978","journal-title":"Acta Derm Venereol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01090","article-title":"High-dose intravenous immunoglobulin in skin autoimmune disease","volume":"10","author":"Hoffmann","year":"2019","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.453","article-title":"Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita","volume":"135","author":"Hirose","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jid.2021.08.448","article-title":"Multiple modes of action mediate the therapeutic effect of intravenous IgG in experimental epidermolysis bullosa acquisita","volume":"142","author":"Pipi","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00362","article-title":"Epidermolysis bullosa acquisita: the 2019 update","volume":"5","author":"Koga","year":"2018","journal-title":"Front Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12726","article-title":"The use of rituximab in treatment of epidermolysis bullosa acquisita: three new cases and a review of the literature","volume":"31","author":"Bevans","year":"2018","journal-title":"Dermatol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2009.02.007","article-title":"Succ\u00e8s de l\u2019association rituximab\u2013cortico\u00efdes g\u00e9n\u00e9raux dans le traitement d\u2019une \u00e9pidermolyse bulleuse acquise r\u00e9calcitrante","volume":"136","author":"Cavailhes","year":"2009","journal-title":"Ann Dermatol V\u00e9n\u00e9r\u00e9ologie."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07596.x","article-title":"A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita","volume":"156","author":"Crichlow","year":"2007","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01360.x","article-title":"Successful treatment of epidermolysis bullosa acquisita with rituximab therapy: letters to the Editor","volume":"39","author":"Kim","year":"2012","journal-title":"J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12006","article-title":"A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy","volume":"31","author":"McKinley","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243432","article-title":"Epidermolysis bullosa acquisita treated with rituximab","volume":"14","author":"Mendes","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.02127.x","article-title":"Fatal pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita","volume":"21","author":"Mercader","year":"2007","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08048.x","article-title":"Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab","volume":"157","author":"Sadler","year":"2007","journal-title":"Br J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03608.x","article-title":"Refractory epidermolysis bullosa acquisita: successful treatment with rituximab","volume":"34","author":"Saha","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.147","article-title":"Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab","volume":"142","author":"Schmidt","year":"2006","journal-title":"Arch Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000106585","article-title":"Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab","volume":"215","author":"Wallet-Faber","year":"2007","journal-title":"Dermatology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023496","article-title":"Epidermolysis bullosa acquisita as an adverse effect from rituximab therapy: a case report","volume":"99","author":"Wu","year":"2020","journal-title":"Med (Baltimore)."},{"key":"B36","article-title":"A case report of the use of rituximab and the epidermolysis bullosa disease activity scoring index (EBDASI) in a patient with epidermolysis bullosa acquisita with extensive esophageal involvement","volume":"26","author":"Yang","year":"2018","journal-title":"Acta Dermatovenerol Croat ADC."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1214011\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T18:35:17Z","timestamp":1689186917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1214011\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2023.1214011"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1214011","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"article-number":"1214011"}}